Latest Prescription Drugs news

American Diabetes Association, June 7-11

The American Diabetes Association 79th Scientific Sessions The annual meeting of the American Diabetes Association was held from June 7 to 11 in San Francisco and attracted approximately 14,000 participants […]

ADA: Combo Injectable Controls Blood Glucose Longer in T2DM

Compared with insulin glargine, initial injectable therapy with a combination of insulin degludec and liraglutide aids achievement of blood glucose goals for a longer period of time in patients with uncontrolled type 2 diabetes on oral antidiabetic drugs, according to a study published online June 9 in The Lancet Diabetes & Endocrinology to coincide with the annual meeting of the American Diabetes Association, held from June 7 to 11 in San Francisco.

ADA: Teplizumab Can Delay T1DM Progression in Those at Risk

A 14-day course of an Fc receptor-nonbinding anti-CD3 monoclonal antibody, teplizumab, can delay progression to type 1 diabetes in individuals at high risk, according to a study published online June 9 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 7 to 11 in San Francisco.

Inappropriate Prescribing Leads to Poor Outcomes in Older Adults

Potentially inappropriate prescribing is tied to increased health care utilization and poor outcomes among older individuals seen in primary care practices, according to a review published in the May/June issue of the Annals of Family Medicine.